The publication of the revised In-Commerce List (ICL) has direct consequences for analytical work supporting substance characterization in the pharmaceutical, food, and personal-product sectors. Under this update, substances retained on the revised list require documented identity and purity data, and laboratories engaged in supporting such submissions need robust methods for structural confirmation and quantitative assay. This article describes the testing pathway associated with the revised ICL in a stepwise manner: the analytical principle applied, the substance scope and affected test objects, sample handling and collection practice, instrumental determination by GC-MS and HPLC, assay performance indicators such as sensitivity and recovery, and the regulatory settings in which the resulting data are used.

Principle & mechanism

Analytical confirmation for revised ICL substances rests on chromatographic separation coupled with structure-specific detection. gas chromatography–mass spectrometry separates volatile and thermally stable compounds on a capillary column, and the mass spectrometer fragments each eluted component in an ion source. The resulting mass spectrum acts as a molecular fingerprint, which the analyst compares against reference libraries or certified reference materials for identification. For non-volatile or thermally labile substances, high-performance liquid chromatography applies the same logic in reverse: separation occurs in the liquid phase, and detection relies on ultraviolet, diode-array, or mass-spectrometric response. Retention time, ion ratios, and spectral match together establish identity, while peak area against a calibration curve yields quantity.

Test objects and substance scope

The revised ICL concerns substances already circulating in Canadian commerce within regulated product categories, principally pharmaceuticals, personal-care formulations, and food-related applications. Test objects therefore include active ingredients, excipients, fragrance components, preservatives, and process-related impurities associated with listed entries. The scope of each engagement is set by the substance entry under review: an entry may cover a discrete chemical identity, a defined mixture, or a class described by generic naming. In practice, the laboratory confirms the identity of the principal component, resolves impurity profiles, and checks consistency between the manufactured material and the description attached to the listing. Both raw materials and finished formulations fall within scope, depending on where the substance enters the supply chain.

Sample types and collection

Samples submitted for revised ICL support work arrive in several forms: neat reference-grade substance, bulk raw material, concentrated intermediate, and finished product extract. Collection follows container-integrity and traceability rules. Solids are sampled with clean inert tools into amber glass vessels; liquids are divided into aliquots large enough for replicate preparation and reanalysis. Labels record batch identity, sampling date, storage condition, and requested determinations. Chain-of-custody documentation accompanies each submission so that results can be tied to a defined material lot. Where the analyte is sensitive to light, oxidation, or moisture, collection uses headspace-minimizing fills and, where warranted, inert-gas overlay. Homogeneity checks precede subsampling, since heterogeneous matrices can bias both identity confirmation and quantitation.

Test methods — GC-MS and HPLC analysis

Method selection follows volatility and thermal behavior. GC-MS suits substances that vaporize without decomposition; analysis typically uses a non-polar or mid-polarity capillary column, programmed temperature ramp, and electron-impact ionization, with selected-ion monitoring adopted when greater selectivity is required. HPLC serves the remaining cases. Reversed-phase separation on a C18 or phenyl-hexyl column, with aqueous-organic gradient elution and volatile buffer salts, covers most neutral and ionizable substances. Diode-array detection supplies UV spectra for identity cross-checking; LC-MS/MS confirmation adds precursor-to-product ion transitions where regulatory scrutiny of the structure is high. Sample preparation ranges from dilute-and-shoot for neat substances to solvent extraction, filtration, and, for complex formulations, solid-phase extraction cleanup before injection.

Assay

performance: sensitivity and recovery
Two indicators govern whether a method is fit for the purpose. Sensitivity is expressed through the limit of detection and limit of quantitation, established from signal-to-noise evaluation or from replicate low-level calibration and reported with the final data. Recovery measures accuracy at spiking levels spanning the expected concentration range; a pre-determined acceptance interval is set before the study, and results falling outside it trigger investigation rather than silent correction. Precision is verified through replicate injections and independent preparations. Specificity is demonstrated by analyzing blank matrix and stressed samples, confirming that no co-eluting interference distorts the target peak. Calibration linearity, verified across the working range, ties the instrumental response to concentration. These parameters are documented in the method validation record accompanying each report.

Application

scenarios and regulatory significance
Data generated under this testing framework serve concrete regulatory purposes connected with the revised ICL publication. Manufacturers and importers use identity and composition reports to substantiate that a material conforms to its listed entry when responding to information requests or updating product notifications. Formulators rely on impurity profiling to judge whether a supplier change alters the substance beyond its listed description. Quality units apply the same assays for lot-release verification and stability monitoring of listed substances in commerce. Because the revised list alters which entries remain eligible for continued sale without further notification, verified analytical identity becomes the practical evidence linking a commercial material to its regulatory listing. Reports are structured accordingly, presenting methods, validation parameters, and results in a format suitable for direct submission.

Quick Answers

Frequently Asked Questions

01

What

does a typical report for the Revised In-Commerce List testing include?
The report generally follows the structure described under test methods and assay performance: substance identification within the applicable scope, GC-MS and HPLC analytical results for the relevant sample types, sensitivity and recovery data, and conclusions tied to regulatory significance. Exact format and content may vary by laboratory.

02

How should submission for Revised In-Commerce List testing be handled, and what communication points matter most?

Submitters should first clarify the substance scope and sample type, since these determine the appropriate collection requirements and analytical method. Key communication points include confirming which GC-MS or HPLC approach applies, the application scenario behind the testing, and how results will support the regulatory purpose.

03

What

factors influence the cost of Revised In-Commerce List testing?
Cost is mainly driven by the substance scope being tested, the sample types submitted, and the choice of test method, since GC-MS and HPLC analyses differ in complexity. Required sensitivity and recovery performance, along with the number of substances and application scenario, also affect overall testing effort and pricing.

← Previous Article Seat belt testing
Next Article → Security door testing

Ready to Discuss Your Testing Needs?

Contact our team for a customized quote and expert consultation on your Update: Publication of the Revised In-Commerce List Testing testing requirements.

Contact Our Team
n n n n n n n n n n